Michał Hawranek

Michał Hawranek

Auto-generated profile, based on publicly available information

Michał Hawranek

3rd Department of Cardiology, School of Medical Sciences in Zabrze, Silesian Center for Heart Diseases, Medical University of Silesia, Katowice, Poland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2013 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
TOTadeusz Osadnik
Tadeusz Osadnik
Joanna Katarzyna StrzelczykJoanna Katarzyna Strzelczyk
Joanna Katarzyna Strzelczyk
MHMichał Hawranek
Michał Hawranek
ALAndrzej Lekston
Andrzej Lekston
JWJarosław Wasilewski
Jarosław Wasilewski
LPLech Poloński
Lech Poloński
Data regarding the association between red cell distribution width (RDW) values and mortality in patients with stable coronary artery disease are scarce. We aimed to investigate the link between mortality and RDW in patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI).

1 September 2018 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
MHMichał Hawranek
Michał Hawranek
MGMarek Gierlotka
Marek Gierlotka
DPDamian Pres
Damian Pres
MZMarian Zembala
Marian Zembala
MGMariusz Gąsior
Mariusz Gąsior

20 September 2016 in Polish Archives of Internal Medicine
Verified
Journal Article
Closed access
MGMariusz Gąsior
Mariusz Gąsior
DPDamian Pres
Damian Pres
WWWojtek Wojakowski
Wojtek Wojakowski
Paweł BuszmanPaweł Buszman
Paweł Buszman
ZKZbigniew Kalarus
Zbigniew Kalarus
MTMichał Tendera
Michał Tendera
INTRODUCTION Despite the progress that occurred in cardiology in the recent years, cardiovascular (CV) diseases still remain the main cause of death in European countries. The knowledge concerning the structure of hospital admissions for CV diseases and clinical outcomes is fragmentary. OBJECTIVES To analyse the characteristics and outcome of patients hospitalised with a CV diagnosis between 2006 and 2014, included in the Silesian Cardiovascular Database (SILCARD). PATIENTS AND METHODS SILCARD is based on the data from the Regional Department of National Health Fund. Enrolment criteria were: hospitalisation at a department of cardiology, cardiac surgery, diabetology or vascular surgery, and hospitalisation with a cardiovascular diagnosis at a department of internal medicine or intensive care. The data come from 310 hospital departments and 1 863 outpatient clinics, and contain information on 487 518 patients and 956 634 hospitalisations. RESULTS Heart failure (HF) (20%) and stable coronary artery disease (SCAD) (18.5%) were the most frequent primary diagnoses. The number of hospitalisations due to HF, aortic stenosis and pulmonary embolism significantly increased. The highest 12-month mortality was noted in patients with HF and pulmonary embolism (>30%). Over the years, 12-month mortality in patients with HF, SCAD, myocardial infarction and atrial fibrillation tended to steadily decrease, but in some areas remained relatively high . CONCLUSIONS Over the period between 2006 and 2014, in-hospital and 12-month mortality remained constant, with a trend for decline in many areas, but considerable space for improvement.

14 April 2017 in Polish Heart Journal
Verified
Journal Article
Closed access
PDF file
MHMichał Hawranek
Michał Hawranek
MGMarek Gierlotka
Marek Gierlotka
MGMariusz Gąsior
Mariusz Gąsior
BHBartosz Hudzik
Bartosz Hudzik
PDPiotr Desperak
Piotr Desperak
LPLech Poloński
Lech Poloński
Background: Impairment of renal function (IRF) is an independent risk factor of myocardial infarction (MI). Aim: The aims of study was to determine if the presence of IRF affects the choice of treatment strategy in patients with MI, and if long-term mortality rates are influenced by the use of invasive strategy in patients with MI according to the grade of IRF. Methods: Data from the PL-ACS Registry of 22,431 patients hospitalized for MI during 2007-2008 with an available estimated glomerular filtration rate (eGFR) with 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula were included. Patients were stratified based on eGFR: ≥90 (normal); 60–89 (mild IRF); 30–59 (moderate IRF); 15–29 (severe IRF); and <15 ml/min/1.73 m2 (end-stage IRF). Results: After adjustment, each increase in IRF grade reduced the likelihood of percutaneous coronary intervention by 19% (odds ratio [OR]: 0.81; 95% confidence interval [CI]: 0.78,0.85; P <0.001). A higher IRF grade was independently associated with mortality (OR: 2.01; 95% CI: 1.86,2.18; P <0.001) and major bleeding (OR: 1.42; 95% CI: 1.22,1.66; P <0.001) during hospitalization, and mortality at 12 (hazard ratio [HR]: 1.55; 95% CI: 1.49,1.62; P <0.001) and 36 months (HR: 1.50; 95% CI: 1.45,1.55; P <0.001). Invasive treatment was independently associated with improved 12-month prognosis in non-ST-segment elevation MI (NSTEMI) patients with mild-to-severe IRF and in ST-elevation MI (STEMI) patients at all IRF grades. Conclusions: Invasive procedures were less frequent with worsening renal dysfunction. Invasive treatment was associated with improved 12-month prognosis in STEMI patients regardless of renal function and in NSTEMI patients with eGFR ≥15 ml/min/1.73 m2. Background: Impairment of renal function (IRF) is an independent risk factor of myocardial infarction (MI). Aim: The aims of study was to determine if the presence of IRF affects the choice of treatment strategy in patients with MI, and if long-term mortality rates are influenced by the use of invasive strategy in patients with MI according to the grade of IRF. Methods: Data from the PL-ACS Registry of 22,431 patients hospitalized for MI during 2007-2008 with an available estimated glomerular filtration rate (eGFR) with 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula were included. Patients were stratified based on eGFR: ≥90 (normal); 60–89 (mild IRF); 30–59 (moderate IRF); 15–29 (severe IRF); and <15 ml/min/1.73 m2 (end-stage IRF). Results: After adjustment, each increase in IRF grade reduced the likelihood of percutaneous coronary intervention by 19% (odds ratio [OR]: 0.81; 95% confidence interval [CI]: 0.78,0.85; P <0.001). A higher IRF grade was independently associated with mortality (OR: 2.01; 95% CI: 1.86,2.18; P <0.001) and major bleeding (OR: 1.42; 95% CI: 1.22,1.66; P <0.001) during hospitalization, and mortality at 12 (hazard ratio [HR]: 1.55; 95% CI: 1.49,1.62; P <0.001) and 36 months (HR: 1.50; 95% CI: 1.45,1.55; P <0.001). Invasive treatment was independently associated with improved 12-month prognosis in non-ST-segment elevation MI (NSTEMI) patients with mild-to-severe IRF and in ST-elevation MI (STEMI) patients at all IRF grades. Conclusions: Invasive procedures were less frequent with worsening renal dysfunction. Invasive treatment was associated with improved 12-month prognosis in STEMI patients regardless of renal function and in NSTEMI patients with eGFR ≥15 ml/min/1.73 m2.


8 August 2023 in Medicina
Verified
Journal Article
Open access
PDF file
MSMichał Rafał Stojko
Michał Rafał Stojko
JNJakub Nocoń
Jakub Nocoń
PPPatrycja Piłat
Patrycja Piłat
GSGabriela Szpila
Gabriela Szpila
JSJoanna Smolarczyk
Joanna Smolarczyk
MHMichał Hawranek
Michał Hawranek
Anabolic-androgenic steroids (anabolic-androgenic steroids, AAS) are testosterone-derived compounds whose popularity and use are constantly growing. Chronic use of AAS leads to many hormonal and metabolic disorders in the human body, which often lead to permanent health damage. Changes affect the following systems: cardiovascular, musculoskeletal, reproductive, digestive, and nervous. We decided to collect the existing knowledge in the literature and enrich it with the latest research reports in the field of degenerative effects of AAS on the nervous system. The work aimed to increase public awareness of the dangers and consequences of AAS use and improve it with the latest research on the neurodegenerative effects of AAS. We hope that our work will contribute to raising public awareness and reducing the use of AAS.